We have developed a hybrid vector that combines the high transduction efficiency of a gene-deleted adenoviral vector and the integration machinery of the bacteriophage-derived integrase FC31 for stable transduction and limited integration sites. We based our system on a two-vector system in which the transgene expression cassette is circularized from a helper-dependent vector by Flp-mediated recombination, followed by FC31-mediated integration. Integration of the transgene expression cassette from the adenoviral vector resulted in 5-fold higher transgene expression levels in the active FC31 group compared to the control group, which received a mutated and inactive version of FC31. We confirmed transgene integration into the previously described mpsL1 hot spot of integration by polymerase chain reaction analyses of DNA isolated from mouse livers. In addition, we cloned 40 integration sites. The hot spot mpsL1 was detected only once, and 44% of all integration events were found to be present in gene regions. With further optimization, this system represents a new tool for gene therapy protocols that may offer an alternative to gene therapy approaches based on random integrating viral vectors.
INTRODUCTION
Successful gene therapy approaches for genetic diseases require sustained and life-long transgene expression levels at a therapeutic range at a non-toxic dose. Integrating viral and non-viral vectors were shown to result in sustained transgene expression levels in vitro and in vivo, but both delivery systems have advantages and disadvantages. In contrast to non-viral vector approaches, viral vectors usually display high transduction efficiencies of the target cell in vitro and in vivo, but the humoral response against incoming capsid proteins and cellmediated immunity remain a major challenge for viral-based gene therapy vector. Furthermore, many virus-based gene transfer approaches are hampered by the risk of insertional mutagenesis. It was shown that retroviral vectors predominantly integrate into active genes 1 and there is strong evidence that integration of recombinant retroviral vector DNA into the host genome was the cause for three leukemia incidences in a human clinical trial for X-linked severe combined immunodeficiency disease. 2, 3 Novel adeno-associated virus (AAV) vectors based on various serotypes were shown to result in long-term transgene expression and high transduction efficiencies in vivo. However, a small percentage of the stably transduced AAV vector DNA in mouse liver integrate into genomic DNA and most of the integration occurs in active genes. 4 In sharp contrast to viral-based gene delivery approaches, non-viral vector systems are less immunogenic and are able to stably maintain vector-encoded transgenes. However, efficient delivery of foreign DNA without toxicity and efficient transduction of the target cell remains a major obstacle. Two non-viral vector systems for somatic integration currently used in gene therapy approaches are based on the Sleeping Beauty (SB) transposase or the bacteriophage integrase FC31 from Streptomyces. SB belongs to the TC1/mariner family of transposable elements and SB-mediated recombination is based on a cut-and-paste mechanism. 5 Recent data from our laboratory demonstrated that sites of insertion after SB-mediated integration are widely distributed but result in a small bias towards genes. 6 In contrast to SB, the bacteriophage integrase FC31 recombines DNA for somatic integration in an unidirectional manner. The recombination process is based on a 2-bp staggered cut followed by rotation of the DNA targets by 1801, which results in integration of foreign DNA. 7 One major advantage of the FC31 integrase is that this recombinase results in integration into limited ''hot spot'' sites in the mammalian genome. 8, 9 This feature of the FC31 integrase would significantly decrease the risk of insertional mutagenesis in a clinical gene therapy setting.
Helper-dependent (HD) adenoviral vectors devoid of all viral coding sequences offer high transduction efficiencies and therapeutic long-term transgene expression levels. [10] [11] [12] [13] Various studies showed that HD vectors result in a significantly reduced cytotoxic response and long-term phenotypic correction in mouse and rat models. 10, 13 After adenoviral transduction, transgene expression levels are initially high but slowly decline over time. 10, 14 The loss of vector genomes and transgene expression after adenoviral gene transfer is at least in part due to the episomal nature of adenoviral vector genomes. Hybrid vectors based on adenovirus for efficient gene delivery and stable transgene expression levels were developed, [15] [16] [17] [18] [19] [20] but for somatic integration into the host genome, recombinases were used, which have a high risk for insertional mutagenesis. Retroviral hybrid vectors with and without retroviral integrase were generated for stable transduction of target cells, but due to the integration pattern of retroviral vectors there was a high risk of insertional mutagenesis. 15, 16 Furthermore adeno-AAV hybrid vectors were generated and integration into the host genome was demonstrated. 17 In a previous study, we generated a gene-deleted adenoviral vector that utilized the SB transposase for stable transgene expression levels in vivo. 18 Although we observed stabilized transgene expression levels during rapid cell cycling of mouse hepatocytes, the SB integration machinery still leads to a random integration pattern that may lead to insertional mutagenesis.
For a safer gene therapy protocol, vectors with high transduction efficiencies that utilize alternative integration machineries for site-specific integration without any detrimental effects on the target cell would be advantageous. It was demonstrated that integration mediated by the bacteriophage integrase FC31 derived from a Streptomyces phage resulted in integration into hot spots of the host genome by recombining the FC31 recognition site attB in an episomal plasmid with pseudo-attP sites in the host chromosome. However, for these non-viral vectors, clinically relevant delivery approaches are still problematic. This study describes the development of a novel hybrid vector that combines high transduction efficiencies of recombinant adenoviral vectors with the best features of the bacteriophage integrase FC31 for stable transduction and limited integration sites.
RESULTS

PhiC3-mediated integration efficiencies from circular and linear substrates
Recombinant adenoviral vector genomes mainly persist as linear DNA molecules. Our previous data demonstrated that Sleeping Beauty-mediated transposition from a gene-deleted adenoviral vector was more efficient from a circular compared to a linear substrate. 18 This motivated us to first compare the FC31-mediated integration efficiencies from circular and linear episomal non-viral DNA. Thus, we performed a colony-forming assay in HeLa cells to determine the integration efficiencies of linear and circular substrates. The same molar amounts of the circular substrate (C)-pCR-attB-Snori and the linear substrate (L)-pCR-attB-Snori that allow for G418 selection in vitro were co-transfected into HeLa cells with a FC31 encoding plasmid ( Figure 1a) . Control groups received either an inactive version of FC31 (m-FC31) or ''stuffer'' DNA co-transfected with the substrates (C)-pCR-attB-Snori or (L)-pCR-attB-Snori, respectively ( Figure 1a) . Fourteen days after selection, a methylene blue staining was performed and cell colonies were counted. We found that the FC31 integration efficiency was 14.8-fold higher from circular substrates (Figure 1b) , and 3.8-fold higher from linear DNA molecules when compared to the mutant integrase control groups (Figure 1b) . The mechanism involved in low-level FC31-mediated integration from linear substrates remains to be determined. In order to improve safety and to avoid integration of the complete linear adenoviral DNA molecule, we based our integrating adenoviral hybrid system on an HD vector in which the transgene expression cassette with the FC31 recognition site attB was flanked by the Flp recombinase recognition sites FRT. In the presence of the Flp recombinase, the transgene expression cassette was excised from the adenoviral vector genome to form a circular substrate followed by FC31-mediated integration (Figure 1c) .
Characterization of the novel hybrid vector system for somatic integration in vitro To generate gene-deleted adenoviral vectors that express the bacteriophage integrase FC31 and the Flp recombinase, we constructed the plasmid pFTC-INT-Flp (Figure 2a ). This vector expresses FC31 under the control of the Rous sarcoma virus (RSV) promoter and Flp recombinase under the control of the elongation factor alpha-1 promoter. As a control, we generated the vector pFTC-mINT-Flp encoding the inactive version of m-FC31. To show the functionality of these plasmid constructs, we performed a colony-forming assay. We co-transfected HeLa cells with the plasmid (C)-pCR-attB-Snori (which allows for G418 selection) with either pFTC-INT-Flp or pFTC-mINT-Flp at a molar ratio of 1:1. Integration efficiencies were 6.2-fold higher for pFTC-INT-Flp compared to the negative control group that received the inactive FC31 mutant plasmid (Figure 2b) .
The HD vector FTC-hFIX-attB-(FRT)2 was used to show in vitro efficacy of the adenovirus-integrase hybrid vector (Figure 3a) . This vector contains a split human coagulation factor IX (hFIX) expression cassette in which the 3 0 cDNA of hFIX and the polyA signal are physically separated by part of the first intron of the hFIX gene from the liver-specific human alpha-1-antitrypsin promoter (hAAT-p) and the 5 0 cDNA. In addition, this split hFIX expression cassette contains the FC31 attachment site, attB, and is flanked by FRT sites for Flpmediated circle formation from the HD adenoviral vector. The hAAT-p can control transgene expression only if the components of the hFIX expression cassette are excised from the HD vector. Huh7 cells were co-transduced with the vector FTC-hFIX-attB-(FRT)2 and the HD vector FTC-INT-Flp (Figure 2a ) at a multiplicity of infection (MOI) of 5.5 each. Control groups received the gene-deleted adenoviral vector FTC-TCM without FRT sites and a split hFIX expression cassette to show that transgene activation is dependent on Flp-mediated excision and circle formation ( Figure 3a) . As a positive control for transgene expression, we infected Huh7 cells with the first-generation adenoviral vector fgAdhFIXmg 10 in which the hFIX expression cassette was not split. After circularization, we detected similar hFIX expression levels for the split hFIX expression cassette and the positive control group, which received fgAdhFIXmg with a regular hFIX expression cassette (Figure 3b) . In sharp contrast, transgene expression levels were 10-fold lower in wells that received the HD vector pFTC-TCM without FRT sites ( Figure  3b) , showing that transgene activation was dependent on Flpmediated excision from the adenoviral vector genome. We speculate that the very low level of detectable hFIX expression in this group may be the result of the formation of circular adenoviral vector genome monomers in which the adenoviral inverted terminal repeats are joined either by homologous recombination or non-homologous end joining because only in the context of this molecular formation can the promoter direct transgene expression.
To further evaluate circle formation, we performed a PCR analysis on DNA isolated from each of the study groups. Primers 1 and 3 detect the HD vector after Flp-mediated recombination and primers 2 and 3 span the FRT site in the gene-deleted adenoviral vector without excision ( Figure 3a) . As expected, we observed excision only in the group that received the adenoviral vector FTC-hFIX-attB-(FRT)2 and not in groups that received either the adenoviral vector FTC-TCM or the first-generation virus fgAdhFIXmg (Figure 3c ). We detected intact HD vector genomes without Flp-mediated excision only in those cells that received the adenoviral vector FTC-TCM (Figure 3c ). To show circle formation in vivo, we co-delivered 1 Â 10 9 transducing Figure 1 Strategy to develop a gene-deleted adenoviral vector that utilizes the bacteriophage integrase FC31 for somatic integration. (a) To determine integration efficiencies from circular and linear substrates after FC31-mediated integration, a colony-forming assay was performed. The circular substrate (C)-pCR-attB-Snori and the linear substrate (L)-pCR-attB-Snori, which allow for G418 selection in vitro, were co-transfected with a FC31 encoding plasmid into HeLa cells. Fourteen days after selection, a methylene blue staining was performed and cell colonies were counted. As controls, either an inactive version of FC31 (m-FC31) or ''stuffer'' DNA was co-transfected. The circular FC31 substrate conferring G418-resistant growth contained a neomycin-resistance gene (neo), the p15 bacterial origin of replication (p15A), the simian virus 40 promoter, the Tn5 promoter, and the integrase FC31 attachment site attB. The linear substrate was generated by restriction enzyme digest of (C)-pCR-attB-Snori. We obtained supra-physiological serum levels of hFIX (up to 54,000 ng/ml, normal level ¼ 5,000 ng/ml) 7 weeks post-injection ( Figure 4a) . In sharp contrast, mice infused with the HD vector containing a split hFIX expression cassette without FRT sites resulted in serum hFIX levels of up to 1,700 ng/ml, establishing Flp-mediated transgene activation. To evaluate in vivo integration of the vector, we induced rapid cell cycling in mouse livers, a process known to eliminate over 95% of episomal genomes ( Figure 4a ). We observed no significant differences between groups that received FC31 or the mutated version of FC31 and this indicated that FC31 expression in the context of this genedeleted adenoviral vector was not sufficient to detect somatic integration by hFIX expression levels. Limited toxicity studies revealed that there was a slight elevation of liver enzymes 1 day post-injection, as demonstrated by serum glutamic pyruvic transaminase (SGPT) levels ( Figure 4b ). We concluded that one reason for this result might have been that FC31 expression levels were not high enough for efficient somatic integration of the transgene or that the molar ratio of the transgene expression cassette and the FC31 and Flp encoding vector was not sufficient to get measurable integtation. We reasoned that one way to optimize the experiment would be to change the ratio of transgene and Flp and FC31 encoding vectors and to simply increase the copy numbers of Flp and FC31 encoding DNA. It is well established that hydrodynamic tail injection results in efficient transduction of up to 40% of all hepatocytes with up to 60 copies per cell even 2 months after injection. 21 A significant increase in the dose of the gene-deleted adenoviral vector encoding for Flp and FC31 most likely would have resulted in transient toxicity and may not have resulted in sufficient FC31 expression levels.
Thus, in our second approach, we performed a study in C57Bl/6 mice in which a FC31 and Flp encoding DNA plasmid was administered into mouse liver by high-pressure tail-vein injection ( Figure 5a) . Four hours later, this step was followed by injection of 5 Â 10 9 TUs of the HD vector FTC-hFIX-attB-(FRT)2 (Figure 3a) with the split hFIX expression cassette (n ¼ 5 per group). Control mice received a plasmid encoding the inactive version of FC31 (m-FC31). At day 52 post-injection, we measured serum hFIX levels of up to 3,000 ng/ml in both groups (Figure 5b) . To confirm integration, we induced rapid cell cycling of mouse hepatocytes by injecting CCl 4 intraperitoneally. With this approach, we observed a 5-fold difference in serum hFIX levels between the active FC31 and the inactive m-FC31 control group, 122 days post-injection (Figure 5b) . At this time, serum hFIX levels were still within the therapeutic range (up to 600 ng/ml or 12% of normal). This observation was in concordance with the total vector genome copy number in mouse livers 122 days post-injection, which were 5-fold higher in the FC31 group compared to the m-FC31 group (Figure 5c Integration site analysis after UC31-mediated integration of the transgene expression cassette from the gene-deleted adenoviral vector into the host genome In order to begin to identify sites of DNA insertion in mouse liver after FC31-mediated integration, we used an established PCR approach ( Figure 6a) . We detected the previously described hot spot of integration mpsL1 on mouse chromosome 2, band H3, in all mouse livers (n ¼ 3) that received the HD vector FTC-hFIXattB-(FRT) 2 and the active bacteriophage integrase (Figure 6a) . In sharp contrast to this observation, there was no PCR product specific for the hot spot mpsL1 in mouse livers (n ¼ 4) that were infused with the HD vector FTC-hFIX-attB-(FRT)2 and the inactive m-FC31 integrase (Figure 6a ). Detailed characterization of PCR products specific for mpsL1 revealed that FC31-mediated integration resulted in micro-deletions of up to 6 bp at the attB arm and up to 20 bp at the chromosomal arm (Figure 6b) .
To determine the overall distribution of integration sites, a modified version of the BD GenomeWalker TM Kit from BD Biosciences Clontech (Palo Alto, CA) was used. To avoid potential unknown biases for detection of integration sites, we created four genomic DNA libraries and we analyzed a total of 40 integration sites in mouse livers that received the HD vector FTC-hFIX-attB-(FRT)2 and the active version of the bacteriophage integrase FC31. Out of 40 integration sites, 34 were mapped on various chromosomes ( Figure 7 ) and although the hot spot of integration, mpsL1, was detected in all analyzed mouse livers using a PCR specific for mpsL1 (Figure 6a) , this site was found only once in the 40 analyzed sites. We found that 15 out of the 34 mapped integration events from the HD vector landed in genes (44.1%), 15 integration sites (44.1%) were found to be intergenic, and 11.7% (4 out 17) of the integration events were in repetitive elements of the mouse genome (all sites of insertion are described in Figure 8) . Out of the 15 identified integration events in genes, 13 were detected in introns, two transgenes landed in exons, whereas no insertion into an untranslated region was found. In sharp contrast to these findings, 94% of all analyzed integration sites (15 out 16 sites of insertion) in control livers that received m-FC31 and the HD vector FTC-hFIX-attB-(FRT)2 had an intact TTG core, indicating that random integration occurred (not shown).
DISCUSSION
We describe a new vector system in which integration from the gene-deleted adenoviral vector was mediated by the FC31 bacteriophage integrase. We demonstrate that this approach results in prolonged transgene expression in vivo even after rapid cell cycling.
Although integration efficiencies were significantly higher from circular substrates, we observed that both supercoiled and linearized DNAs were suitable substrates for recombination between attP and attB in mammalian cells (Figure 1b) .
Currently, we can only speculate about the mechanism involved in FC31-mediated integration from linear fragments. One possibility would be that double-stranded linear DNA in the cell is converted into circular DNA molecules by non-homologous end joining. One might also speculate that FC31 integrase is involved in the formation of circular DNA for integration. Linear DNA fragments can indeed serve as substrates for FC31-mediated recombination between attP and attB 22 in bacteria. In an earlier study, we found that SB-mediated integration was not sufficient to mediate transposition from a linear substrate. 18 However, there are fundamental mechanistic differences in the integration process between SB and the bacteriophage integrase FC31. In contrast to FC31, which works by a 2-bp staggered break followed by integration of the complete DNA fragment, the SB transposase works by a cut-andpaste mechanism.
We based our integrating adenoviral hybrid system on an HD vector in which the transgene expression cassette with the FC31 recognition site attB is flanked by the Flp recombinase recognition sites FRT. In the presence of the Flp recombinase, the transgene expression cassette is excised from the adenoviral vector genome to form a circular substrate followed by FC31-mediated integration. One reason for this strategy was that FC31-mediated integration efficiencies were higher from circular substrates compared to linear substrates. However, low-level random integration of linear adenoviral vector genomes was demonstrated 23 and a recent report described homologous recombination of adenoviral DNA sequences and endogenous sequences in mouse embryonic stem cells. 24 Random integration of recombinant viral vector DNA may present a safety concern for our system. Therefore, excision of the transgene from the adenoviral vector followed by FC31-mediated integration may decrease random integration of the complete linear adenoviral DNA molecule into the host genome 9 TU was injected, which equaled a total dose of 2 Â 10 9 TU per mouse. Serum samples were obtained periodically by retro-orbital bleeding and an ELISA was performed. To induce cell cycling of mouse hepatocytes in vivo, we performed a surgical two-third partial hepatectomy (ph) and we injected CCl 4 . Mean7SD is shown (n ¼ 3/group). (b) SGPT levels from single mice 1 day post-injection. Serum samples from all three experimental groups were obtained for colorimetric determination of SGPT levels. As a negative control, regular C57Bl/6 mice (naïve mice) were added. Mean7SD is shown (n ¼ 4/group).
and with regard to gene therapy it may improve safety of this novel vector system.
After in vivo delivery of our new adenoviral hybrid vector utilizing FC31 for somatic integration, we were able to detect the previously described hot spot of FC31-mediated integration mpsL1 in all mouse livers as demonstrated by an established PCR protocol. 25 This finding is in concordance with previous studies in which the same hot spot was detected in mouse liver after non-viral delivery of the FC31 integration machinery.
9,25
Furthermore, we were interested in the overall distribution of all integration sites in vivo. We were able to identify and characterize a total of 40 sites of insertion in mouse liver after FC31-mediated integration. Out of these 40 integration events, we recovered the hot spot mpsL1 in mouse liver once. This finding may indicate that the bacteriophage integrase FC31 may be less specific than originally thought. This finding is in concordance with a recent study demonstrating that there are more varied hot spots in various cell types in vitro. 26 There is one previous report in which a total of two sites of integration were recovered from mouse liver by nested inverse PCR in a non-viral gene therapy approach and the predominant site of insertion was mpsL1. 9 We believe that there may be several reasons for these differences between our study and the historical data. First of all, integration site selection may be different in a non-viral gene therapy approach compared to a viral gene transfer system. Our strategy was based on FC31-mediated integration from a genedeleted adenoviral vector in which the adenoviral vector contained the transgene and two non-viral vectors encoding for FC31 and Flp recombinase. It may be possible that FC31-mediated integration combined with adenoviral transduction of hepatocytes and coexpression of Flp recombinase in the target cell might have caused a different integration pattern compared to a non-viral approach. Another explanation for the less specific integration pattern observed in this study may be the strategy chosen to determine integration sites.
We performed a detailed characterization of sites of insertion and found that 44.1% of all rescued sites of insertion were in genes. Furthermore, we found the same percentage (44.1% of all sites of insertion) of integrated transgenes in intergenic regions. A recent study in which an extensive analysis of sites of insertion in vitro was performed also showed a small bias toward integration into genes. 26 This feature of our adeno-integrase hybrid system may represent fundamental advantages compared to other integrating viral vector systems that utilize recombinases or integrases that predominantly target genes. However, with respect to integration into genes, these characteristics are similar to the integration pattern of the SB transposase. 6 Various adenoviral hybrid vectors for somatic integration were generated in the past. In sharp contrast to our novel integrating adenoviral hybrid vector, these previously published reports utilized recombinases and integrases with an integration pattern that may result in insertional mutagenesis. Thus, our vector system provides the important advantage of limited integration site selection and with further optimization we believe that this novel integrating adenoviral system presented in this study will significantly reduce the risk of insertional mutagenesis. There was one recent report introducing a gene-deleted adenoviral vector that utilized the Rep68/78 protein from AAV for integration into the natural integration site AAVS1 on human chromosome 19. 27 However, there is strong evidence that Rep proteins are toxic to the cell. In addition, the integration efficiencies of this system in human cells remain to be determined.
Further studies need to address the possibility to create a hybrid vector system in which the bacteriophage recombinase FC31 encoding expression cassette, the Flp recombinase encoding DNA, and the transgene with the attB site are encoded by one-gene-deleted adenoviral vector. A ratio of 1:1 (substrate:FC31) in a non-viral approach resulted in efficient integration of foreign DNA into the host genome, but a ratio of 1:1 using a two-vector system based on adenovirus did not result in measurable integration efficiencies. An inducible system in which the FC31 integrase is expressed under the control of an inducible promoter might be advantageous because long-term expression of the FC31 integrase might result in unwanted events. With further improvements of recombinases or other proteins that offer site-specific integration, it may be possible to generate in future a hybrid vector system that lessens the risk of insertional mutagenesis.
MATERIALS AND METHODS
DNA constructs for generation and production of adenoviral vectors. The gene-deleted adenoviral vector pAdFTC 10 and the split hFIX expression cassette 18 were described previously. Instead of the inverted repeats for SB-mediated transposition, this split hFIX expression cassette contained the FC31 recognition site attB for FC31-mediated integration between the liver-specific promoter and the polyA signal. This split hFIX expression cassette contains a liver-specific promoter, the first exon of the hFIX coding sequence, and part of the first intron of the hFIX gene. These DNA sequences are physically separated from the 3 0 end of the first intron of the hFIX gene, the 3 0 end of the hFIX coding sequence, and the polyA signal. The split FIX expression cassette was flanked by the Flp recognition sites FRT and all DNA sequences were cloned into the plasmid pAdFTC to generate pFTC-hFIX-attB-(FRT)2. A physical map of this vector is depicted in Figure 3a . The gene-deleted adenoviral vector with the identical transgene expression cassette but without FRT sites was called FTC-TCM. Further details about the cloning strategy can be obtained upon request. The plasmids pFlp, pCMV-INT, and pCMV-mINT were described elsewhere. 25, 28 Briefly, expression of Flp recombinase, FC31, and the mutated and inactive version of the bacteriophage integrase was driven by the cytomegalovirus promoter. To generate the HD vectors pFTC-INT-Flp and pFTC-mINT-Flp for adenoviral production, we ligated SpeI/BamHI fragments from pCMV-INT and pCS-mINT into the NheI/BglII sites of pRSV-mcs-BpA resulting in the vectors pRSV-INT and pRSV-mINT. In order to obtain the plasmids pHD-Flp-INT and pHD-Flp-mINT, we inserted the XhoI/SspI fragments from pRSV-INT and pRSV-mINT into the SmaI and BsmI sites of pHD-SB-Flp-DNot by bluntend ligation. To generate the vectors pFTC-INT-Flp and pFTC-mINT-Flp for adenoviral production, the PacI/PmeI fragments from pHD-Flp-INT and pHD-Flp-mINT were cloned into the PacI/PmeI site of pAdFTC.
Adenoviral vector production. HD adenoviral production was based on a recently published system. 29 In brief, to release the plasmid Mapped integration sites are depicted by arrows and the two previously described hot spots of integration, mpsL1 and mpsL2, are marked by a square. The BD GenomeWalker TM Kit from BD Biosciences Clontech was adopted to determine sites of insertion. Four genomic DNA libraries with restriction enzyme endonucleases that create blunt-ended DNA fragments (DraI, EcoRV, PvuII, SspI) were produced and a linker was ligated to the DNA fragments. A two-step PCR was performed in which one primer binds to the attB arm and the other primer binds to the linker (primer pair for first PCR: AttB-F, 5
0 -tac cgt cga cga tgt agg tca cgg tc-3 0 and adopter primer 1 (AP1), 5 0 -gta ata cga ctc act ata ggg c-3 0 ; primer pair for the nested PCR: AttB-F3, 5
0 -cga agc cgc ggt gcg-3 0 and adopter primer 2 (AP2), 5 0 -act ata ggg cac gcg tgg t-3 0 ). PCR products were subcloned and DNA sequences analyzed.
Molecular Therapy vol. 15 no. 1, jan. 2007 backbone, the plasmids pFTC-hFIX-attB-(FRT)2, pFTC-INT-Flp, and pFTC-mINT-Flp were linearized by NotI digest and transfected into 116 cells, 29 which stably express Cre recombinase, using Superfect tranfection reagent (Qiagen, Valencia, CA). Sixteen hours post-transfection, cells were transfected with the helper virus AdNG163R-2 29 at an MOI of 5 and cells were harvested 48 h later. We performed three serial passaging steps using an MOI of 2 of the helper virus AdNG163R-2. According to the published protocol by Palmer and Ng, 29 3 l of 116 cells was grown and amplified as a suspension culture in a spinner culture flask (Bellco Glass, Vineland, NJ) and infected with the lysate of one 150 mm dish from serial passaging step three. Forty-eight hours after infection, cells were harvested and to purify the recombinant vector we performed one CsCl step gradient followed by one equilibrium gradient (20 h, CsCl 1.35 g/cm 3 ). For buffer exchange, we dialyzed the purified virus in 10 mM Tris (pH 7.5), 10% (v/v) glycerol, and 1 mM MgCl 2 . DNA sequences contained in the first-generation adenoviral vector fgAdhFIXmg (E1/E3 deleted) and amplification and purification of this recombinant adenoviral vector were described elsewhere. 10 Titering of helper-dependent vectors. The number of transducing particles contained in the final HD vector preparations was determined as follows: HeLa cells were infected with different volumes of the HD vector preparation. For comparison, HeLa cells were infected at different defined MOIs with the first-generation adenovirus fgAdhFIX 10 to generate a standard curve. Cells were incubated for 3 h and the genomic DNA was isolated followed by a Southern blot probed with either an hFIX cDNA probe (HindIII/EcoRI fragment from plasmid AAVEF1alpha-F.IX 30 ) for pFTC-hFIX-attB-(FRT)2 or a probe containing the left adenoviral inverted terminal repeat with the packaging signal for pFTC-INT-Flp and pFTC-mINT-Flp. The intensity of the bands for the HD vector was compared to the standard curve. z NCBI Blast of the mouse genome gave no hit; DNA sequence was not mapped and therefore no further information about the characteristics of this site of insertion was available.
either no virus or the previously described first-generation adenovirus fgAdhFIXmg 10 in which the hFIX expression cassette was not split as a positive control. Media were changed daily and the supernatant was analyzed for hFIX expression levels by enzyme-linked immunosorbent assay (ELISA). Four days post-transduction, cells were harvested and genomic DNA isolated to check if Flp-mediated circle formation from the adenoviral vector genome occurred. In brief, after proteinase K digest, a phenol/chloroform extraction was performed followed by ethanol precipitation. A PCR was performed with the primers FTC-240 (5 0 -ctt gta tgt gtt ggg aat tca tcg-3 0 ) and FTC-547 (5 0 -gct gtt tgc tgc ttg caa tgt ttg-3 0 ), which are located outside of the FRT sites of the vector pFTC-hFIX-attB-(FRT)2. If the transgene is excised, a 1-kb PCR product will be obtained. To show Flp-mediated excision in vivo, genomic DNA was isolated from mouse liver after co-delivery of 1 Â 10 9 TU of the HD vector FTC-hFIX-attB-(FRT)2 and 1 Â 10 9 TU of the second HD vector FTC-INT-Flp encoding Flp and FC31.
Cell culture. HeLa cells were maintained in Dulbecco's modified Eagle's medium (Cellgro, Herndon, VA) supplemented with L-glutamine (Gibco BRL, Carlsbad, CA), penicillin/streptomycin (Gibco BRL), and fetal bovine serum (10%). The human hepatoma cell line Huh7 was maintained in Dulbecco's modified Eagle's medium media (Cellgro) supplemented with L-glutamine (Gibco BRL), penicillin/streptomycin (Gibco BRL), nonessential amino acids (Gibco BRL), and fetal bovine serum (10%). For genedeleted adenoviral production, 116 cells were maintained in minimal essential media (Cellgro) supplemented with L-glutamine (Gibco BRL) and penicillin/streptomycin (Gibco BRL) and fetal bovine serum (10%). First-generation adenovirus was amplified in the human embryonic kidney cell line 293 maintained in Dulbecco's modified Eagle's medium media (Cellgro) supplemented with L-glutamine (Gibco BRL), penicillin/ streptomycin (Gibco BRL), and fetal bovine serum (10%).
Animal studies. C57Bl/6 mice (Jackson Laboratories, Bar Harbor, ME) were kept under the Stanford animal facility regulations. C57Bl/6 mice (8-10 weeks old) were injected via high-pressure tail-vein injection as previously described. 25 In brief, the 20 mg plasmid DNA was diluted in 2.0 ml of a physiological 0.9% (w/v) NaCl solution and injected into the mouse tail vein over a time period of 5-7 s. Adenovirus was diluted in Dulbecco's phosphate buffered saline and a total volume of 200 ml Dulbecco's phosphate buffered saline (Gibco BRL). Rapid cell cycling of mouse hepatocytes was induced by injecting CCl 4 intraperitoneally and by performing a surgical two-third partial hepatectomy.
Blood analysis. Mouse serum human FIX antigen levels were determined by ELISA assay as described earlier. 10 The normal human serum level was 5,000 ng/ml. SGPT (alanine aminotransferase activity) assays were performed by using a diagnostic kit for colorimetric determination of SGPT (Sigma procedure no. 505-OP).
Colony-forming assay. To determine the integration efficiencies of linear and circular substrates for FC31-mediated integration, a colonyforming assay was performed in HeLa cells. HeLa cells were plated at a density of 5 Â 10 5 cells per 6-cm dish and transfected 24 h later with Superfect (Qiagen). The constructs (C)-pCR-attB-Snori (circular FC31 substrate) 25 and (L)-pCR-attB-Snori (linear FC31 substrate) for FC31-mediated integration were transfected into HeLa cells with the active version of the FC31 (FC31) integrase or the mutated FC31 integrase (m-FC31). As a negative control, we co-transfected the linear and circular substrates with ''stuffer'' DNA derived from the plasmid pBluescript (Stratgene, La Jolla, CA). Both substrates contained the FC31 recognition site attB and a neomycin expression cassette for expression in mammalian cells, which allows for cell growth in selective media containing G418. The linear phiC31 substrate was produced by digest of (C)-pCR-attB-Snori with the restriction enzyme endonucleases NotI and SpeI. For transfection, 2 mg of the linear or circular substrate and the FC31 or m-FC31 encoding plasmid was transfected. Additional control groups received 2 mg of either the linear or the circular substrate and ''stuffer'' DNA. Forty-eight hours after transfection, the cells were diluted into 10-cm dishes at a density of either 3.8 Â 10 4 or 3.8 Â 10 5 cells per 10-cm dish. Cells were selected for 14 days with G418-containing media (500 mg/ml). A methylene blue staining was performed and cell colonies counted.
To test if DNA sequences contained in the plasmids pFTC-INT-Flp and pFTC-mINT-Flp are sufficient to integrate substrates for FC31-mediated integration, we performed a colony-forming assay. We cotransfected HeLa cells with the plasmid (C)-pCR-attB-Snori and either pFTC-INT-Flp or pFTC-mINT-Flp at a molar ratio of 1:1, respectively. After 2 weeks of G418 selection (500 mg/ml), we performed a methylene blue staining and cell colonies were counted.
Analyses of integration events in mouse liver from a gene-deleted adenoviral vector. For genomic DNA isolation, the mouse liver was removed and homogenized, and a 100-mg portion was used for DNA extraction. Mouse liver genomic DNA was isolated by proteinase K digest followed by phenol/chloroform extraction and ethanol precipitation. The BD GenomeWalker TM Kit from BD Biosciences Clontech was adopted to determine sites of insertion. Four genomic DNA libraries with restriction enzyme nucleases that create blunt-ended DNA fragments (DraI, EcoRV, PvuII, SspI) were produced and a linker was ligated to the DNA fragments. A two-step PCR was performed in which one primer binds to the attB arm and the other primer binds to the linker (primer pair for first PCR: AttB-F, 5 0 -tac cgt cga cga tgt agg tca cgg tc-3 0 and adopter primer 1, 5 0 -gta ata cga ctc act ata ggg c-3 0 ; primer pair for the nested PCR: AttB-F3, 5 0 -cga agc cgc ggt gcg-3 0 and adopter primer 2, 5 0 -act ata ggg cac gcg tgg t-3 0 ). PCR products were subcloned and the sequences analyzed.
Detection and characterization of the mpsL1 integration sites in mouse liver. Genomic DNA from mouse liver was isolated and a PCR with the two mpsL1 integration site-specific primers MpsL1 forward (5 0 -gtg gca cat tcc tta atc cc-3 0 ) and MpsL1 reverse (5 0 -tga gga gga gcc tta gca ac-3 0 ), which were combined with the attB-specific primer AttB-F (5 0 -tac cgt cga cga tgt agg tca cgg tc-3 0 ), was performed. This first PCR was followed by a second PCR in which the primer attB-F3 (5 0 -cga agc cgc ggt gcg-3 0 ) was combined with either MpsL1 forward or MpsL1. To determine the DNA sequences of the resulting PCR products, the DNA fragments were subcloned using a TA-cloning kit (Invitrogen, Carlsbad, CA) and sequenced. As internal control, the interleukin 2 DNA (IL-2) was detected with the following primers: IL-2 5 0 (5 0 -cta ggc cac aga att gaa aga tct-3 0 ) and IL-2 3 0 (5 0 -gta ggt gga aat tct agc atc atc c-3 0 ).
Quantification of genome copy numbers in mouse hepatocytes. To detect the total copy number per cell, a quantitative real-time PCR was performed (GeneAmp s 5700 Sequence Detection System, PE Biosystems, Foster City, CA). Genomic DNA from mouse liver was isolated and 10 ng of liver genomic DNA was analyzed using a SYBR Green kit (PE Biosystems ). The following conditions were used: 40 cycles at 951C for 15 s and 601C for 1 min. The PCR product is located in the hFIX cDNA (nt 5,032-5,800 from pBS-ApoEHCR(s)-hAATp-hFIXmg-bpA 31 ) and for the amplification an hFIX forward primer (5 0 -aag atg cca aac cag gtc aat t-3 0 ) and an hFIX reverse primer (5 0 -gat aga gcc tcc aca gaa tgc a-3 0 ) were used. To generate a standard curve, we used 10, 100, 1,000, 10,000, 100,000, and 1,000,000 copies of the plasmid pBS-ApoEHCR(s)-hAATp-hFIXmg-bpA 31 spiked with genomic DNA.
